• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Hims & Hers Heath Shares Are Surging Today

    7/22/24 3:23:33 PM ET
    $HIMS
    $NVO
    $TEVA
    Medical/Nursing Services
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HIMS alert in real time by email

    Hims & Hers Health Inc. (NYSE:HIMS) shares are moving higher on Monday after the company appointed former Novo Nordisk COO and President Kåre Schultz‘s to its Board of Directors.

    Schultz brings extensive experience from his leadership roles at Novo Nordisk Inc.  (NYSE:NVO), Teva Pharmaceutical Industries LTD (NYSE:TEVA) and Lundbeck.

    At Novo Nordisk, Schultz was instrumental in establishing the company as a leader in diabetes care.

    “Kåre’s experience gives us an incredible wealth of expertise as we bring together the most valuable elements of clinical excellence, healthcare and technology to redefine health and wellness for our customers.” said CEO Andrew Dudum.

    Price Action: Hims & Hers shares were up by 5.12% at $20.50 at the time of writing, according to Benzinga Pro.

    See Also:

    • Biden’s Exit From Presidential Race ‘Yet Another Curveball For Equity Investors’: Analysts

    Image: Courtesy of Hims & Hers Health, Inc.

    Get the next $HIMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS
    $NVO
    $TEVA

    CompanyDatePrice TargetRatingAnalyst
    Novo Nordisk A/S
    $NVO
    1/27/2026Neutral
    Citigroup
    Hims & Hers Health Inc.
    $HIMS
    1/12/2026$33.00In-line
    Evercore ISI
    Teva Pharmaceutical Industries Limited
    $TEVA
    12/9/2025$35.00Overweight
    Barclays
    Hims & Hers Health Inc.
    $HIMS
    12/9/2025$48.00Overweight
    Barclays
    Novo Nordisk A/S
    $NVO
    12/8/2025Buy → Hold
    Argus
    Teva Pharmaceutical Industries Limited
    $TEVA
    12/5/2025$35.00Sector Outperform
    Scotiabank
    Novo Nordisk A/S
    $NVO
    10/27/2025Underperform
    Jefferies
    Hims & Hers Health Inc.
    $HIMS
    10/21/2025Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $HIMS
    $NVO
    $TEVA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr

    3/8/24 2:00:18 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HIMS
    $NVO
    $TEVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Legal Officer Mcavoy David R. bought $20,988 worth of Ordinary Shares (1,113 units at $18.86), increasing direct ownership by 9% to 13,027 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    9/9/25 4:02:56 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    11/14/24 4:57:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/24 4:16:26 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    $NVO
    $TEVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Okupe Oluyemi exercised 5,262 shares at a strike of $5.01 and sold $139,108 worth of shares (5,262 units at $26.44) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    2/4/26 4:13:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by EVP, Chief Financial Officer Kalif Eliyahu Sharon

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    1/29/26 4:07:39 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by See "Remarks" Hughes Eric A

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    1/29/26 4:05:58 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HIMS
    $NVO
    $TEVA
    SEC Filings

    View All

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    2/9/26 8:32:09 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    2/5/26 2:56:38 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    2/5/26 2:55:18 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HIMS
    $NVO
    $TEVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026

    San Francisco, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Weight management concerns should be evaluated by a qualified healthcare professional. Hims GLP-1 Weight Loss is a prescription-only medication program available exclusively through licensed physician consultation. This content does not diagnose, treat, cure, or prevent any disease. Prescription approval is not guaranteed. If you purchase through links in this article, a commission may be earned at no additional cost to you. Purpose and Scope This release is an informational overview of publicly available disclosures for Hims GLP-1 Weight Loss

    2/5/26 8:51:30 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy®**. This needle-free treatment joins a full suite of weight loss solutions designed to meet the specific needs and preferences of individual customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205680502/en/ By leveraging nearly a decade of infrastructure investment to drive radical affordability, Hims & Hers is making personalized care more accessible than ever.

    2/5/26 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care

    The company will offer access to Galleri®, an innovative blood test from GRAIL, Inc. that screens for more than 50 types of cancer Today, Hims & Hers Health, Inc. (NYSE:HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a simple cancer screening blood test that can detect a signal for 50+ types of cancer even before symptoms appear1. This multi-cancer early detection (MCED) test combines Hims & Hers' scale with GRAIL's innovative cancer screening technology to dramatically increase access to proactive care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026

    2/4/26 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    $NVO
    $TEVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Novo Nordisk A/S

    Citigroup initiated coverage of Novo Nordisk A/S with a rating of Neutral

    1/27/26 8:47:55 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evercore ISI initiated coverage on Hims & Hers Health with a new price target

    Evercore ISI initiated coverage of Hims & Hers Health with a rating of In-line and set a new price target of $33.00

    1/12/26 8:13:43 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Barclays initiated coverage on Teva Pharma with a new price target

    Barclays initiated coverage of Teva Pharma with a rating of Overweight and set a new price target of $35.00

    12/9/25 8:54:12 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HIMS
    $NVO
    $TEVA
    Financials

    Live finance-specific insights

    View All

    Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the c

    2/2/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

    Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 billion, growing 34% YoY in LC. AJOVY® global revenues of $673 million, up 30% YoY in LC.UZEDY® revenues of $191 million, up 63% YoY in LC; underscoring Teva's commitment to drive new advances in neuroscience: Fastest growing long-acting injectable (LAI)1FDA expanded indicati

    1/28/26 7:00:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

    Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-‘408TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (NASDAQ:RPRX), today announced a funding agreement of up to $500 million to accel

    1/11/26 5:00:00 PM ET
    $RPRX
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HIMS
    $NVO
    $TEVA
    Leadership Updates

    Live Leadership Updates

    View All

    Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges

    First cohort features 7 real-world challenges across R&D, manufacturing and supply chain, commercial and medical affairs Teva's first-ever global innovation platform aims to accelerate patient impact and drive business transformation, as part of its Pivot to Growth StrategyRise will enable startups and tech players worldwide to validate their solutions in real-world settings, scaling impact across Teva's global ecosystem including in the U.S., Europe, Israel and beyond TEL AVIV, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today unveiled Teva Rise, a global open innovation platform designed to harness the power of a variety of disruptive tech

    11/19/25 8:00:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company's global public policy, regulatory, and government affairs functions. A former senior leader at the FDA, prosecutor f

    11/17/25 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

    6/26/25 11:44:00 AM ET
    $ADCT
    $CTOR
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HIMS
    $NVO
    $TEVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

    SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    11/12/24 10:34:14 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care